AbbVie Vs. Pfizer: Impact Of The Inflation Reduction Act On Their Future

Aug. 19, 2022 5:48 PM ETAbbVie Inc. (ABBV) Stock, PFE Stock, , , , , , , , , , 39 Comments
Nathan Aisenstadt
5.15K Followers

Summary

  • Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ.
  • AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year.
  • It is unlikely that the Inflation Reduction Act will have a strong impact on the financial position of Pfizer and AbbVie.
  • Both companies have high dividend yields that will be of interest to long-term investors.
  • Pfizer's total debt is $32.7 billion lower than AbbVie's.
The Inflation Reduction Act of 2022 and cash on it.

designer491

Pfizer (NYSE:PFE) is one of the largest pharmaceutical companies that continues to increase its share of the COVID-19 treatment market. Seizing the momentum, the company continues to reinvest the revenue from the sales of the COVID-19 portfolio into the acquisition of

This article was written by

5.15K Followers
I am an independent research analyst focused on finding undervalued assets with above-average growth rates and developments that can dramatically improve the company's financial position. When investing, I use medium-term and long-term trading strategies that take into account psychological and behavioral variables and are able to mitigate the risks associated with macroeconomic and geopolitical instability.The main sectors of analysis are industrials, consumer staples, technology, and healthcare.When analyzing assets in the healthcare sector, in addition to examining their financial position, I delve into the safety and efficacy data of the company's product candidates from preclinical and clinical studies, allowing me to evaluate their commercial prospects. While the education received at the Hebrew University of Jerusalem contributes to a comprehensive and detailed analysis of biotechnological and physicochemical processes used in the production of goods in the agricultural, oil and gas, and chemical industries. As a result, it allows me to find the most promising assets in a rapidly changing market and publish meaningful articles on Seeking Alpha.My e-mail for any questions and suggestions: aisenathan@gmail.com

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article may not take into account all the risks and catalysts for the stocks described in it. Any part of this analytical article is provided for informational purposes only, does not constitute an individual investment recommendation, investment idea, advice, offer to buy or sell securities, or other financial instruments. The completeness and accuracy of the information in the analytical article are not guaranteed. If any fundamental criteria or events change in the future, I do not assume any obligation to update this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABBV

Related Stocks

SymbolLast Price% Chg
PFE
--
ABBV
--